HARP News and Press, Harpoon Therapeutics Inc. From 04/07/22

SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that Natalie Sacks, M.D., Chief Medical Officer, will be leaving the company effective June 1, ...

Harpoon Therapeutics Inc. (NASDAQ:HARP) traded at a new 52-week high today of $25.05. Approximately 10.9 million shares have changed hands today, as compared to an average 30-day volume of 503,000 shares. Over the past year, Harpoon Therapeutics Inc. has traded in a range of $3.30 to $24...

SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a fireside chat at the Canaccord Genuity Horizons in Oncolo...

Several Street firms have lowered their price targets for Harpoon Therapeutics (HARP -10.9%) though are keeping either buy or overweight ratings. Shares are down 11% in late morning trading. Piper Sandler's Joseph Catanzaro lowered his target to $15 from $27 (~282% return based on F...

The clinical-stage immunotherapy company Harpoon Therapeutics (HARP -34.8%) have lost more than a third on Friday after announcing its plans to discontinue the clinical work on HPN424, an experimental therapy for prostate cancer. The decision followed “a careful and thorough analysis o...

Harpoon Therapeutics press release (NASDAQ:HARP): Q4 GAAP EPS of -$0.66 misses by $0.23. Revenue of $4.3M (-42.7% Y/Y) misses by $1.9M. For further details see: Harpoon Therapeutics GAAP EPS of -$0.66 misses by $0.23, revenue of $4.3M misses by $1.9M

SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a co...

The clinical-stage immunotherapy company, Harpoon Therapeutics (NASDAQ:HARP) announced on Monday that the U.S. Food and Drug Administration (FDA) granted the Orphan Drug Designation for its investigational product, HPN328, for the treatment in small cell lung cancer (SCLC). HPN328, designed b...

SOUTH SAN FRANCISCO, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN328...

Clinical-stage biotech, Harpoon Therapeutics (NASDAQ:HARP) announced on Wednesday that the U.S. Food and Drug Administration (FDA) granted the Fast Track designation for HPN217, a potential treatment for multiple myeloma. The FDA has issued the Fast Track designation for HPN217 in the treatme...